Hornig, Mady, Montoya, José G, Klimas, Nancy G et al. · Science advances · 2015 · DOI
This study found that people with ME/CFS have distinctive patterns of immune system markers in their blood, but only early in the disease. Researchers compared blood samples from 52 people with early-stage ME/CFS to 348 healthy people and 246 people with long-standing ME/CFS. The early-stage group showed heightened immune activity that was not present in people who had been sick longer, suggesting the disease's immune profile changes over time.
This research is significant because it identifies objective blood-based signatures that could enable earlier diagnosis of ME/CFS—a disease currently diagnosed only by clinical criteria. The finding that immune markers change with disease duration provides a biological explanation for why previous biomarker studies produced inconsistent results and suggests that sampling timing is critical for future diagnostic test development.
This study does not prove that these immune alterations cause ME/CFS or that they are sufficient for diagnosis on their own. The cross-sectional design means we cannot establish whether these immune changes persist in early-stage patients or how they predict outcomes. It also does not explain why immune signatures normalize in longer-duration cases or whether this represents true resolution or adaptive changes.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.